Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Hypomethylating agent based combinations in MDS

Thomas Prebet • 18 Nov 2020
ASH 2020
Myelodysplastic Syndromes Venetoclax

Thomas Prebet, MD, PhD, Yale School of Medicine, New Haven, CT, discusses a key strategy to find novel agents to use in combination with hypomethylating agents (HMAs) in higher-risk myelodysplastic syndromes (MDS). The end goal is to improve patient outcomes while mitigating increased side effects, such as hematological toxicity, that are often intolerable in vulnerable populations. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Thomas Prebet, MD, PhD, has done consultancy work for BMS and AbbVie and has received research support from BMS and Jazz.

More from Thomas Prebet

3:31
Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
Thomas Prebet • 18 Nov 2020
2:19
AML: what to look forward to at ASH 2020
Thomas Prebet • 18 Nov 2020
1:19
New treatments for AML
Thomas Prebet • 7 Oct 2020
1:51
Treating AML patients who are not eligible for intensive chemotherapy
Thomas Prebet • 7 Oct 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals